Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,792

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2030

Study Completion Date

September 30, 2033

Conditions
High-risk Melanoma
Interventions
DRUG

nivolumab or pembrolizumab

See above

All Listed Sponsors
collaborator

Karolinska University Hospital

OTHER

collaborator

Skane University Hospital

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Norrlands University Hospital

OTHER

collaborator

Region Örebro County

OTHER

collaborator

University Hospital, Linkoeping

OTHER

collaborator

Karlstad Central Hospital

OTHER

collaborator

Västmanland County Council, Sweden

OTHER_GOV

collaborator

Gävle Hospital

OTHER

collaborator

Falu Hospital

OTHER

lead

Uppsala University

OTHER